News
IPHA
1.520
+2.70%
0.040
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
TipRanks · 1d ago
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Barchart · 2d ago
Weekly Report: what happened at IPHA last week (1019-1023)?
Weekly Report · 2d ago
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Barchart · 10/21 00:00
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Barchart · 10/20 00:00
Weekly Report: what happened at IPHA last week (1012-1016)?
Weekly Report · 10/19 09:09
Weekly Report: what happened at IPHA last week (1005-1009)?
Weekly Report · 10/12 09:09
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
NASDAQ · 10/05 12:35
Weekly Report: what happened at IPHA last week (0928-1002)?
Weekly Report · 10/05 09:09
Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22
NASDAQ · 10/02 11:44
H.C. Wainwright Remains a Buy on Innate Pharma (IPHA)
TipRanks · 10/01 14:36
Weekly Report: what happened at IPHA last week (0921-0925)?
Weekly Report · 09/28 09:09
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
NASDAQ · 09/23 16:00
Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)
TipRanks · 09/21 10:40
Weekly Report: what happened at IPHA last week (0914-0918)?
Weekly Report · 09/21 09:09
BTIG Remains a Buy on Innate Pharma (IPHA)
TipRanks · 09/18 10:55
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript
The Motley Fool · 09/18 03:07
Innate Pharma Price Target Maintained With a $9.00/Share by BTIG
Dow Jones · 09/17 16:01
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target
Benzinga · 09/17 15:51
Innate Pharma H1 2026 Earnings Call Transcript
Benzinga · 09/17 12:27
More
Webull provides a variety of real-time IPHA stock news. You can receive the latest news about Innate Pharma Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.